Logo image of HROWM

HARROW INC - HROW 11 7/8 12/31/27 (HROWM) Stock Fundamental Analysis

NASDAQ:HROWM - Nasdaq - US4158583074 - Currency: USD

26.235  -0.46 (-1.74%)

Fundamental Rating

5

HROWM gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. HROWM has a medium profitability rating, but doesn't score so well on its financial health evaluation. HROWM is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year HROWM has reported negative net income.
HROWM had a negative operating cash flow in the past year.
In the past 5 years HROWM always reported negative net income.
In multiple years HROWM reported negative operating cash flow during the last 5 years.
HROWM Yearly Net Income VS EBIT VS OCF VS FCFHROWM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

The Return On Assets of HROWM (-4.49%) is better than 74.24% of its industry peers.
HROWM's Return On Equity of -25.10% is fine compared to the rest of the industry. HROWM outperforms 65.15% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.41%, HROWM is in the better half of the industry, outperforming 78.28% of the companies in the same industry.
HROWM had an Average Return On Invested Capital over the past 3 years of 1.25%. This is significantly below the industry average of 41.51%.
The 3 year average ROIC (1.25%) for HROWM is below the current ROIC(2.41%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -4.49%
ROE -25.1%
ROIC 2.41%
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
HROWM Yearly ROA, ROE, ROICHROWM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

With a decent Operating Margin value of 4.55%, HROWM is doing good in the industry, outperforming 77.27% of the companies in the same industry.
In the last couple of years the Operating Margin of HROWM has grown nicely.
With an excellent Gross Margin value of 75.33%, HROWM belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
HROWM's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 4.55%
PM (TTM) N/A
GM 75.33%
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
HROWM Yearly Profit, Operating, Gross MarginsHROWM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HROWM is destroying value.
The number of shares outstanding for HROWM has been increased compared to 1 year ago.
Compared to 5 years ago, HROWM has more shares outstanding
Compared to 1 year ago, HROWM has an improved debt to assets ratio.
HROWM Yearly Shares OutstandingHROWM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
HROWM Yearly Total Debt VS Total AssetsHROWM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

HROWM has an Altman-Z score of 2.19. This is not the best score and indicates that HROWM is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of HROWM (2.19) is better than 71.21% of its industry peers.
HROWM has a Debt/Equity ratio of 3.15. This is a high value indicating a heavy dependency on external financing.
HROWM's Debt to Equity ratio of 3.15 is on the low side compared to the rest of the industry. HROWM is outperformed by 80.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.15
Debt/FCF N/A
Altman-Z 2.19
ROIC/WACC0.23
WACC10.34%
HROWM Yearly LT Debt VS Equity VS FCFHROWM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

HROWM has a Current Ratio of 2.08. This indicates that HROWM is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HROWM (2.08) is comparable to the rest of the industry.
HROWM has a Quick Ratio of 1.96. This is a normal value and indicates that HROWM is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.96, HROWM perfoms like the industry average, outperforming 43.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 1.96
HROWM Yearly Current Assets VS Current LiabilitesHROWM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.78% over the past year.
HROWM shows a strong growth in Revenue. In the last year, the Revenue has grown by 53.32%.
The Revenue has been growing by 31.29% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
Revenue 1Y (TTM)53.32%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%38.29%

3.2 Future

HROWM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 135.76% yearly.
HROWM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 51.08% yearly.
EPS Next Y213.59%
EPS Next 2Y143.81%
EPS Next 3Y135.76%
EPS Next 5YN/A
Revenue Next Year45.22%
Revenue Next 2Y41.06%
Revenue Next 3Y51.08%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HROWM Yearly Revenue VS EstimatesHROWM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
HROWM Yearly EPS VS EstimatesHROWM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

HROWM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
HROWM is valuated correctly with a Price/Forward Earnings ratio of 15.12.
HROWM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. HROWM is cheaper than 79.29% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.27, HROWM is valued a bit cheaper.
Industry RankSector Rank
PE N/A
Fwd PE 15.12
HROWM Price Earnings VS Forward Price EarningsHROWM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

HROWM's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. HROWM is cheaper than 75.76% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 48.79
HROWM Per share dataHROWM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

HROWM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as HROWM's earnings are expected to grow with 135.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y143.81%
EPS Next 3Y135.76%

More info and screens

5

5. Dividend

5.1 Amount

HROWM has a Yearly Dividend Yield of 11.12%, which is a nice return.
HROWM's Dividend Yield is rather good when compared to the industry average which is at 4.22. HROWM pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, HROWM pays a better dividend.
Industry RankSector Rank
Dividend Yield 11.12%

5.2 History

HROWM has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
HROWM Yearly Dividends per shareHROWM Yearly Dividends per shareYearly Dividends per share 2023 2024 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

DP0%
EPS Next 2Y143.81%
EPS Next 3Y135.76%
HROWM Yearly Income VS Free CF VS DividendHROWM Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

More info and screens

HARROW INC - HROW 11 7/8 12/31/27

NASDAQ:HROWM (5/16/2025, 8:00:01 PM)

26.235

-0.46 (-1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners59.06%
Inst Owner ChangeN/A
Ins Owners13.21%
Ins Owner ChangeN/A
Market Cap962.56M
Analysts83.64
Price Target63.12 (140.59%)
Short Float %0%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield 11.12%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years1
Div Non Decr Years1
Ex-Date04-15 2025-04-15 (0.7421875)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)45.74%
Min EPS beat(2)-127.34%
Max EPS beat(2)218.83%
EPS beat(4)2
Avg EPS beat(4)4.78%
Min EPS beat(4)-127.34%
Max EPS beat(4)218.83%
EPS beat(8)2
Avg EPS beat(8)-179.73%
EPS beat(12)4
Avg EPS beat(12)-1142.72%
EPS beat(16)5
Avg EPS beat(16)-963.58%
Revenue beat(2)1
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-8.55%
Max Revenue beat(2)6.04%
Revenue beat(4)2
Avg Revenue beat(4)0.93%
Min Revenue beat(4)-8.55%
Max Revenue beat(4)12.87%
Revenue beat(8)4
Avg Revenue beat(8)-0.66%
Revenue beat(12)6
Avg Revenue beat(12)-0.05%
Revenue beat(16)10
Avg Revenue beat(16)1.76%
PT rev (1m)7.13%
PT rev (3m)34.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-180.82%
EPS NY rev (1m)-5.41%
EPS NY rev (3m)-13.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 15.12
P/S 4.82
P/FCF N/A
P/OCF N/A
P/B 13.82
P/tB N/A
EV/EBITDA 48.79
EPS(TTM)-0.56
EYN/A
EPS(NY)1.74
Fwd EY6.62%
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS5.44
BVpS1.9
TBVpS-3.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.49%
ROE -25.1%
ROCE 3.05%
ROIC 2.41%
ROICexc 2.86%
ROICexgc 11.32%
OM 4.55%
PM (TTM) N/A
GM 75.33%
FCFM N/A
ROA(3y)-7.09%
ROA(5y)-9.18%
ROE(3y)-36.88%
ROE(5y)-57.31%
ROIC(3y)1.25%
ROIC(5y)1.34%
ROICexc(3y)2.44%
ROICexc(5y)3.09%
ROICexgc(3y)9.66%
ROICexgc(5y)8.29%
ROCE(3y)1.58%
ROCE(5y)1.69%
ROICexcg growth 3Y16.24%
ROICexcg growth 5YN/A
ROICexc growth 3Y-9.77%
ROICexc growth 5YN/A
OM growth 3Y20.78%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5Y2.29%
F-Score5
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 3.15
Debt/FCF N/A
Debt/EBITDA 9.3
Cap/Depr 265.5%
Cap/Sales 19.33%
Interest Coverage 0.44
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.08
Quick Ratio 1.96
Altman-Z 2.19
F-Score5
WACC10.34%
ROIC/WACC0.23
Cap/Depr(3y)528.86%
Cap/Depr(5y)344.75%
Cap/Sales(3y)46.48%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.58%
EPS Next Y213.59%
EPS Next 2Y143.81%
EPS Next 3Y135.76%
EPS Next 5YN/A
Revenue 1Y (TTM)53.32%
Revenue growth 3Y40.17%
Revenue growth 5Y31.29%
Sales Q2Q%38.29%
Revenue Next Year45.22%
Revenue Next 2Y41.06%
Revenue Next 3Y51.08%
Revenue Next 5YN/A
EBIT growth 1Y1027.33%
EBIT growth 3Y69.3%
EBIT growth 5YN/A
EBIT Next Year1568.1%
EBIT Next 3Y280.43%
EBIT Next 5YN/A
FCF growth 1Y59.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-678.18%
OCF growth 3YN/A
OCF growth 5YN/A